Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Crinetics Pharmaceuticals (CRNX) Leases (2019 - 2025)

Crinetics Pharmaceuticals has reported Leases over the past 7 years, most recently at $40.5 million for Q4 2025.

  • For Q4 2025, Leases fell 6.93% year-over-year to $40.5 million; the TTM value through Dec 2025 reached $40.5 million, down 6.93%, while the annual FY2025 figure was $40.5 million, 6.93% down from the prior year.
  • Leases for Q4 2025 was $40.5 million at Crinetics Pharmaceuticals, down from $41.1 million in the prior quarter.
  • Over five years, Leases peaked at $48.0 million in Q3 2023 and troughed at $1.3 million in Q2 2023.
  • A 5-year average of $22.8 million and a median of $21.3 million in 2021 define the central range for Leases.
  • Biggest five-year swings in Leases: decreased 26.16% in 2023 and later surged 3492.18% in 2024.
  • Year by year, Leases stood at $1.9 million in 2021, then decreased by 21.46% to $1.5 million in 2022, then soared by 3032.5% to $46.5 million in 2023, then dropped by 6.54% to $43.5 million in 2024, then dropped by 6.93% to $40.5 million in 2025.
  • Business Quant data shows Leases for CRNX at $40.5 million in Q4 2025, $41.1 million in Q3 2025, and $41.9 million in Q2 2025.